论文部分内容阅读
目的比较瑞格列奈和格列吡嗪治疗老年初发2型糖尿病的疗效差异。方法将80例老年初发2型糖尿病患者随机分成治疗组与对照组,分别给予瑞格列奈与格列吡嗪治疗,观察治疗后患者血糖、糖化血红蛋白、空腹C肽、血脂、体质量变化及不良反应。结果2组对血糖、糖化血红蛋白有相似的降低效果(P<0.05),但治疗组更优。2组空腹C肽治疗后均较治疗前明显增加,但组间无明显差异(P>0.05)。治疗组发生低血糖反应几率小。结论瑞格列奈与格列吡嗪对老年初发2型糖尿病患者有相似的降糖效果,但瑞格列奈控制糖化血红蛋白、保护胰岛β细胞功能方面优于格列吡嗪。
Objective To compare the efficacy of repaglinide and glipizide in the treatment of type 2 diabetes in elderly patients. Methods Eighty elderly patients with newly diagnosed type 2 diabetes mellitus were randomly divided into treatment group and control group. The patients were treated with repaglinide and glipizide respectively. The changes of blood glucose, glycosylated hemoglobin, fasting C-peptide, blood lipid and body weight were observed after treatment And adverse reactions. The results of two groups of blood glucose, glycosylated hemoglobin have a similar reduction (P <0.05), but the treatment group is better. The fasting C-peptide levels in both groups were significantly higher than those before treatment, but there was no significant difference between the two groups (P> 0.05). The incidence of hypoglycemia in treatment group is low. Conclusions Repaglinide and glipizide have similar hypoglycemic effects on type 2 diabetes in elderly patients. However, repaglinide is superior to glipizide in controlling glycosylated hemoglobin and protecting islet β-cell function.